Horizon Pharma Public Limited Company, a biopharmaceutical company, focuses on researching, developing, and commercializing medicines that address unmet treatment needs for rare and rheumatic diseases in the United States and internationally. The company's marketed medicine portfolio consists of RAVICTI for the treatment of urea cycle disorders; PROCYSBI to treat nephropathic cystinosis; ACTIMMUNE for the treatment of chronic granulomatous disease and malignant osteopetrosis; BUPHENYL to treat urea cycle disorders; and QUINSAIR for the treatment of chronic pulmonary infections due to pseudomonas aeruginosa in cystic fibrosis patients. Its products also include KRYSTEXXA to treat chronic refractory gout; RAYOS/LODOTRA for the treatment of rheumatoid arthritis, polymyalgia rheumatic, systemic lupus erythematosus, and various other indications; PENNSAID 2% to treat pain of osteoarthritis of the knees; DUEXIS for the treatment of signs and symptoms of osteoarthritis and rheumatoid arthritis; VIMOVO to treat signs and symptoms of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis; and MIGERGOT for the treatment of vascular headache. The company has collaboration agreement with Fox Chase Cancer Center to evaluate ACTIMMUNE in combination with PD-1/PD-L1 inhibitors in various forms of cancer; Alliance for Lupus Research to evaluate RAYOS/LODOTRA on the fatigue experienced by systemic lupus erythematosus patients; Syneos Health, Inc. in connection with its Phase III confirmatory trial to evaluate teprotumumab for the treatment of thyroid eye disease; and HemoShear Therapeutics, LLC to discover and develop therapeutics for gout. Horizon Pharma Public Limited Company was founded in 2005 and is headquartered in Dublin, Ireland.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
Phone011-353-1772-2100
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$1.06 billion
Profitability
Miscellaneous
Employees1,010
OptionableOptionable
Horizon Pharma (NASDAQ:HZNP) Frequently Asked Questions
What is Horizon Pharma's stock symbol?
Horizon Pharma trades on the NASDAQ under the ticker symbol "HZNP."
How will Horizon Pharma's stock buyback program work?
Horizon Pharma announced that its Board of Directors has initiated a stock repurchase plan on Sunday, June 4th 2017, which allows the company to buyback 1,000% of shares, according to EventVestor. This buyback authorization allows the company to buy shares of its stock through open market purchases. Shares buyback plans are generally a sign that the company's board of directors believes its stock is undervalued.
How were Horizon Pharma's earnings last quarter?
Horizon Pharma PLC (NASDAQ:HZNP) released its quarterly earnings data on Wednesday, August, 8th. The biopharmaceutical company reported $0.48 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.31 by $0.17. The biopharmaceutical company had revenue of $302.84 million for the quarter, compared to analyst estimates of $275.51 million. Horizon Pharma had a negative net margin of 18.70% and a positive return on equity of 27.14%. The firm's revenue was up 4.6% on a year-over-year basis. During the same period in the previous year, the firm posted $0.41 earnings per share. View Horizon Pharma's Earnings History.
When is Horizon Pharma's next earnings date?
How can I listen to Horizon Pharma's earnings call?
Horizon Pharma will be holding an earnings conference call on Wednesday, February 27th at 8:00 AM Eastern. Interested parties can register for or listen to the call using this link.
What price target have analysts set for HZNP?
12 analysts have issued 12 month price targets for Horizon Pharma's stock. Their forecasts range from $18.00 to $35.00. On average, they anticipate Horizon Pharma's stock price to reach $23.7273 in the next twelve months. This suggests a possible upside of 2.4% from the stock's current price. View Analyst Price Targets for Horizon Pharma.
What is the consensus analysts' recommendation for Horizon Pharma?
12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Horizon Pharma in the last year. There are currently 4 hold ratings and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Horizon Pharma.
What are Wall Street analysts saying about Horizon Pharma stock?
Here are some recent quotes from research analysts about Horizon Pharma stock:
- 1. According to Zacks Investment Research, "Horizon faces intense competition from pharmaceutical and biotechnology companies, and universities and other research institutions.Horizon is working on label expansion of drug like Ravicti. Failing to gain regulatory approval for label expansions would hamper drugs’ commercial potential. The company is exploring a broader clinical profile of Krystexxa including adapting its MIRROR immunomodulation study based on promising recent data to support the potential for registration.The company’s clinical programs continue to advance, with the recent presentation of new teprotumumab phase II data that underscore the durable efficacy observed in thyroid eye disease. Shares of the company have outperformed the industry in the past year. Estimates have remained stable ahead of the Q4 results. The company has positive earnings surprise in the last few quarters." (2/8/2019)
- 2. Mizuho analysts commented, "We believe the event could have +10% upside/-30% downside to the stock (and is risky), because expectations for a positive read-out are already quite high. HZNP already advanced +17% YTD into the event. The company has discussed with us the opportunity as capturing 50% share in the 15,000-20,000 moderate/ severe active TED patients, with a $100K net price for treatment to achieve its estimates of >$750M. In contrast, we currently assume a ~15% share, and net price of $210K/treatment in 2020, with net price increases of 5% thereafter (based on prior mgmt. commentary on Orphan pricing). We will update our estimates after the data, which we believe will determine the commercial attractiveness of this compound. We reiterate our Neutral rating, and continue to view 2019 consensus earnings estimates as too high." (2/7/2019)
- 3. Cantor Fitzgerald analysts commented, ". We are raising our 12-month PT for HZNP shares to $23 from $21. The increase in our PT is driven by multiple expansion. We think this is deserved because continued solid execution from the management team underscores our belief that the peak sales potential of HZNP’s orphan/rare disease as well as rheumatology businesses are underappreciated." (10/18/2018)
- 4. Cowen Inc analysts commented, "Sarepta (SRPT) reported 2Q18 sales/earnings and provided a business update on 8/8. Exondys51 sales of $74M topped our expectations (see below) by 5%, and accelerated sequentially in 2Q18, after a slight dip in 1Q18. However, SRPT kept its FY18 guidance unchanged. OPEX is increasing faster than expectations, with FY18E non-GAAP OPEX potentially >2X 2016 levels of $198M. With sales growth starting to slow to high single digits Q/Q, focus is increasingly turning to the early/mid-stage pipeline to deliver commercial products in the near term. We continue to believe that gene therapy projects will take a minimum of 3-5 years to get to market and the exon- skipping agents (53 & 45) on-market by 2020. We stay neutral on the name." (8/9/2018)
Has Horizon Pharma been receiving favorable news coverage?
Headlines about HZNP stock have trended somewhat positive recently, InfoTrie Sentiment reports. The research group scores the sentiment of media coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Horizon Pharma earned a news sentiment score of 1.6 on InfoTrie's scale. They also gave press coverage about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the stock's share price in the next several days.
Who are some of Horizon Pharma's key competitors?
Some companies that are related to Horizon Pharma include Ono Pharmaceutical (OPHLF), Merck KGaA (MKGAF), GRIFOLS S A/S (GRFS), Genmab A/S (GNMSF), Sarepta Therapeutics (SRPT), Bausch Health Companies (BHC), Alnylam Pharmaceuticals (ALNY), Ionis Pharmaceuticals (IONS), Beigene (BGNE), Jazz Pharmaceuticals (JAZZ), SAGE Therapeutics (SAGE), Nektar Therapeutics (NKTR), Loxo Oncology (LOXO), Marina Biotech (MRNA) and Perrigo (PRGO).
Who are Horizon Pharma's key executives?
Horizon Pharma's management team includes the folowing people:
- Mr. Timothy P. Walbert, Chairman, Pres & CEO (Age 52)
- Mr. Paul W. Hoelscher, Exec. VP & CFO (Age 54)
- Mr. Barry J. Moze, Exec. VP & Chief Admin. Officer (Age 65)
- Ms. Irina Konstantinovsky, Exec. VP & Chief HR Officer (Age 49)
- Mr. Miles W. McHugh, Chief Accounting Officer & Sr. VP (Age 54)
Who are Horizon Pharma's major shareholders?
Horizon Pharma's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (8.29%), Dimensional Fund Advisors LP (3.07%), venBio Select Advisor LLC (2.60%), D. E. Shaw & Co. Inc. (2.01%), Eagle Asset Management Inc. (1.61%) and Northern Trust Corp (1.39%). Company insiders that own Horizon Pharma stock include Brian K Beeler, Geoffrey M Curtis, Michael G Grey, Robert Carey and Timothy P Walbert. View Institutional Ownership Trends for Horizon Pharma.
Which major investors are selling Horizon Pharma stock?
HZNP stock was sold by a variety of institutional investors in the last quarter, including Bank of America Corp DE, Brandywine Global Investment Management LLC, Dimensional Fund Advisors LP, Segall Bryant & Hamill LLC, Barings LLC, Bank of Montreal Can, venBio Select Advisor LLC and Prudential Financial Inc.. Company insiders that have sold Horizon Pharma company stock in the last year include Brian K Beeler, Geoffrey M Curtis and Timothy P Walbert. View Insider Buying and Selling for Horizon Pharma.
Which major investors are buying Horizon Pharma stock?
HZNP stock was bought by a variety of institutional investors in the last quarter, including D. E. Shaw & Co. Inc., Emerald Advisers LLC, Emerald Mutual Fund Advisers Trust, Jennison Associates LLC, Two Sigma Investments LP, Two Sigma Advisers LP, Penserra Capital Management LLC and Oak Ridge Investments LLC. View Insider Buying and Selling for Horizon Pharma.
How do I buy shares of Horizon Pharma?
Shares of HZNP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Horizon Pharma's stock price today?
One share of HZNP stock can currently be purchased for approximately $23.17.
How big of a company is Horizon Pharma?
Horizon Pharma has a market capitalization of $3.88 billion and generates $1.06 billion in revenue each year. The biopharmaceutical company earns $-410,520,000.00 in net income (profit) each year or $1.18 on an earnings per share basis. Horizon Pharma employs 1,010 workers across the globe.
What is Horizon Pharma's official website?
How can I contact Horizon Pharma?
Horizon Pharma's mailing address is 1 BURLINGTON ROAD CONNAUGHT HOUSE 1ST FLOOR, DUBLIN L2, D04 C5Y6. The biopharmaceutical company can be reached via phone at 011-353-1772-2100 or via email at [email protected]
MarketBeat Community Rating for Horizon Pharma (NASDAQ HZNP)
MarketBeat's community ratings are surveys of what our community members think about Horizon Pharma and other stocks. Vote "Outperform" if you believe HZNP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe HZNP will underperform the S&P 500 over the long term. You may vote once every thirty days.
